In the Clinic
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
Knocking Out KRAS-Mutant Cancers with a One-Two Punch
A new approach aims to combine two existing targeted therapy drugs to attack lung cancer and pancreatic cancer with mutations in the hard-to-target gene KRAS.
In the Lab
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Researchers are developing uses for a drug that could benefit many people with lung cancer.
In the Clinic
FDA Approval Gives Hope to Some People with Advanced Colorectal Cancer
A new treatment is approved for an especially aggressive kind of colorectal cancer.
In the Lab
Outsmarting Cancer’s Survival Skills
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
Profile
At Work: Physician-Scientist David Solit
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Honors
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.
